Evaluation of A live trivalent vaccine for infectious bovine rhinotracheitis virus, para-influenza type-3 virus and Pasteurella multocida in calves.
A live trivalent vaccine for Infectious Bovine Rhinotracheitis virus (IBR), Para-influenza type-3 virus (PI3) and Pasteurella multocida type B vaccine was prepared. The preparation contained 10(7) TCID50 of IBR, 10(7) TCID50 of PI3 & 10(9) CFU of P. multocida type B per 3 ml. Ten calves (5-7 days old) were vaccinated intranasally while five unvaccinated calves of the same age were used as control. Vaccinated calves were examined daily for disease manifestation. Serum and nasal secretion specimens were collected prevaccination and at 7, 15, 21, 30, 45 and 60 days following vaccination. The results indicated that, intranasal vaccination with the live trivalent vaccine stimulates the development of satisfactory level of circulating and mucosal antibodies. It is concluded that the prepared vaccine may be useful for controlling Bovine respiratory disease in calves.
Saoud
Aboul
A
Veterinary Serum and Vaccine Research Institute, Abbassia, Cairo, Egypt.
El Sayed
M
M
Zedan
S M
SM
Wasel
M S
MS
El-Sawalhy
A A
AA
D000818:Animals; D002417:Cattle; D002418:Cattle Diseases / Q000276:immunology / Q000517:prevention & control*; D005260:Female; D007242:Herpesvirus 1, Bovine / Q000276:immunology; D007070:Immunoglobulin A / Q000097:blood; D016233:Immunotherapy, Active; D007241:Infectious Bovine Rhinotracheitis / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D010224:Parainfluenza Virus 3, Human / Q000276:immunology; D010326:Pasteurella Infections / Q000276:immunology / Q000517:prevention & control*; D016979:Pasteurella multocida / Q000276:immunology; D010253:Respirovirus Infections / Q000276:immunology / Q000517:prevention & control*; D013997:Time Factors; D017778:Vaccines, Combined / Q000627:therapeutic use*
D007070:Immunoglobulin A; D017778:Vaccines, Combined